Rocket Pharmaceuticals/$RCKT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Rocket Pharmaceuticals

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Ticker

$RCKT
Sector
Primary listing

Employees

299

RCKT Metrics

BasicAdvanced
$358M
-
-$2.49
0.65
-

What the Analysts think about RCKT

Analyst ratings (Buy, Hold, Sell) for Rocket Pharmaceuticals stock.

Bulls say / Bears say

Rocket plans to conserve its $318.2 million cash reserves, which could fund operations through 2027 and support ongoing research and development in its gene therapy pipeline.
The company’s RP-A601 program for PKP2-ACM has received the FDA’s RMAT (Regenerative Medicine Advanced Therapy) designation, granting access to intensive guidance and potentially accelerated review that could speed up development and possible approval.
The FDA has cleared Rocket’s IND application for RP-A701 and granted Fast Track designation for its BAG3-DCM gene therapy candidate, expanding its clinical pipeline and strengthening its long-term growth outlook.
The FDA has paused Rocket’s Phase 2 pivotal trial of RP-A501 after a patient died from capillary leak syndrome, delaying a program seen as a major revenue source and raising safety concerns.
Rocket has announced it will lay off 30% of its workforce and will halt investment in its Fanconi Anemia and Pyruvate Kinase Deficiency programs, marking a contraction of its pipeline that could limit future diversification.
After news of the FDA's trial suspension was released, Rocket’s shares dropped more than 60%, highlighting deep investor skepticism and increased volatility around its main program.
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.

RCKT Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

RCKT Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RCKT

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs